Haemolysis assays examine disruption of red blood cells by measuring released haemoglobin. They are often placed beside antimicrobial results, but the resulting percentage is a specific laboratory endpoint. Its interpretation depends on the cells, comparison controls and tested exposure, and it cannot stand in for a complete assessment of biological safety.
Identify what the percentage represents
Greco and colleagues’ original comparative study measured haemoglobin release and expressed haemolysis relative to control observations. The study evaluated red cells from several species and examined other toxicity models separately.Greco and colleagues — Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides (opens in a new tab)
Start with the raw measurement and the control definitions. A percentage of a reference lysis signal is not a direct count of every damaged cell unless the study has demonstrated that relationship.
Find how background release was handled. The untreated preparation can have its own signal, so a small absolute reading and a small background-corrected effect are not interchangeable descriptions.
If the candidate material affects optical measurement, that possibility needs to be addressed when interpreting haemoglobin-associated absorbance. Read the relevant blank and interference evidence rather than assume every colour change comes from cells.
The result should remain attached to the tested sample. It is evidence about the material present in that experiment, not automatic validation of every product sold under the same peptide name.
Separate a tested percentage from a fitted threshold
| Finding | Defensible reading |
|---|---|
| 3% at the highest tested level | A low measured response at that level under these conditions |
| 50% response observed within the range | A midpoint may be estimated if the data and model support it |
| 50% response never observed | The midpoint was not directly resolved by the tested range |
These are fictional reporting situations. The first does not establish a precise concentration at which half lysis would occur. Extending a fitted curve beyond observed responses can create a number with much more apparent certainty than the data justify.
Read abbreviations such as HC10 and HC50 against the paper’s definitions. A concentration linked with 10% haemolysis and one linked with 50% haemolysis are different endpoints.
For cross-study comparisons, align the endpoint before comparing values. A lower reported number may simply reflect a lower percentage criterion.
Also preserve greater-than signs where the threshold was not reached. A bound is useful information and should not be converted into an exact value for a ranking table.
Keep the red-cell model visible
The species comparison in Greco and colleagues’ study found different erythrocyte sensitivities to its peptide set. That finding argues against treating red cells from different species as interchangeable evidence for these assays.Greco and colleagues — Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides (opens in a new tab)
Record species and sample provenance, together with the preparation and exposure window. A result described only as non-haemolytic omits the model in which that statement was tested.
Two studies using the same species can still differ in their experimental context. The appropriate response to an apparent disagreement is to compare those details before concluding that one molecular result must be wrong.
The point is to preserve what makes the experiment interpretable. A concise summary can include the cell source and observation time without reproducing a laboratory protocol.
Keep selectivity ratios in perspective
An article may divide a haemolysis-related concentration by an antimicrobial concentration to describe experimental selectivity. Read both definitions and units before interpreting that ratio.
If one input is only a bound, the ratio also carries that limitation. An exact-looking quotient should not replace an unresolved threshold.
The ratio compares two selected assay endpoints. It does not encompass all cell types, organ responses or exposure conditions, and should not be presented as a proven safety margin for human use.
A careful conclusion reports the observed red-cell effect and any separately measured cellular outcomes. Keeping those observations distinct makes haemolysis useful as one piece of evidence without giving it a broader meaning than the study supports.
Sources and further detail
- Greco and colleagues — Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides (opens in a new tab)
Original 2020 abstract, comparative results and haemoglobin-measurement description read. Brief paraphrase of endpoint and species dependence. No reported dosing, peptide ranking or safety recommendation reproduced; threshold examples are original.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.